Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them ...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines ...

Coegi used more than 500 million impressions and paid social optimized with attention and emotion metrics to drive 24% of ...

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work ...

Think Tank Transcripts:Who Owns History? MR. WATTENBERG ... I think what revisionists, ifyou want to call them that, are pointing out is that the historicaldevelopment set in motion or symbolized ...

Just ask Brad Miller, Chief Information Officer (CIO) of Moderna. Brad is passionate about ... Our job is to help them be educated on the use of AI, including examples of use cases that we see ...

Know other book lovers who might like this guide? Forward them this email. When you buy a book using a link in this newsletter, we receive a commission. Thank you for supporting The Atlantic.

18 analysts have expressed a variety of opinions on Moderna (NASDAQ ... the changing sentiments over the past 30 days and comparing them to the preceding months. The 12-month price targets ...

Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. Vandana Singh Benzinga Bulls And ...

I cover tax, budget and retirement policy from Washington The federal government wants to know more, and wants consumers to know more, about who owns nursing homes. It is about time. And it may ...

It's been a sad week for Moderna, Inc. ( NASDAQ:MRNA ), who've watched their investment drop 14% to US$46.83 in the... On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1. ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...